ANDA 90268, held by Sciegen Pharms. Levofloxacin.
As of Nov 16, 2026, ANDA 90268 (Levofloxacin), held by Sciegen Pharms, was first approved by FDA on Dec 20, 2010, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 20, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levofloxacin0.5% · solution/drops;ophthalmic | Levofloxacin | Discontinued |
| Feb 7, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 20, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters